- Global Pharma News & Resources

Two Journal Articles Cite Cleanascite™ in Studies of Lipid Influences in Cell Response Assays

Two Journal Articles Cite Cleanascite™ in Studies of Lipid Influences in Cell Response Assays


MONMOUTH JUNCTION, NJ, September 9, 2021 -- Biotech Support Group reports on two articles describing the simplicity and efficiency of their lipid depletion technology to determine the influence of lipids in cellular response assays. The first citation is:


Chen, Hsin-Yi, et al. "Selective abrogation of S6K2 maps lipid homeostasis as a survival vulnerability in MAPKi-resistant NRASmut melanoma." bioRxiv (2021).


The article reports that silencing of the ribosomal protein S6 kinase 2 (S6K2), while preserving the activity of S6K1, perturbs lipid metabolism, enhances fatty acid unsaturation, triggers lipid peroxidation and induces cell death selectively in NRAS-mutant melanoma cells that are resistant to MAPK inhibition. To help identify cell response factors, the article states “Lipid-depleted serum (FBS) was prepared by treating with Cleanascite reagent at a volume ratio of 1:4 per the manufacturer’s instructions.” The study establishes S6K2 and its effector subnetwork as promising targets for NRAS-mutant melanoma that are resistant to global MAPK pathway inhibitors.


The second citation is:

Pointner, Lisa, et al. "Birch pollen induces Toll-like receptor 4-dependent dendritic cell activation favoring T cell responses.Frontiers in Allergy (2021): 42.


This study aimed to examine (i) the importance of Toll-like receptor 4 (TLR4) for dendritic cell (DC) activation by birch pollen extracts (BPE), (ii) the extent of the contribution of BPE-derived lipopolysaccharide (LPS) and other potential TLR4 adjuvant(s) in BPE, and (iii) the relevance of the TLR4-dependent activation of BPE-stimulated DCs in the initiation of an adaptive immune response. The article states “To remove the lipids in BPE, CleanasciteTM  was used …according to manufacturer's recommendations … in a ratio 1:1 (v/v). Importantly, “non-specific treatment-associated and cytotoxic effects were ruled out …as neither the protein digestion nor the lipid extraction procedure affected cell activation.” These findings suggest that TLR4 is a major pathway by which BPE triggers DC activation that is involved in the initiation of adaptive immune responses.


“As these new citations attest, Cleanascite™ has become the go-to product for lipid removal in the most challenging applications. Whenever an investigation needs to consider whether lipids influence cell culture response, Cleanascite™ can be used. It is an aqueous suspension product without harmful solvents, or any other non-specific cytotoxic effects. This ultimately helps researchers decide whether or not lipids, or factors interacting with lipids, impart characteristic changes in cells.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group

Click to download whitepaper entitled “Cleanascite™ -  Lipid Removal and Cell Response Applications

Click to visit Cleanascite™ product page and ordering information

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to                                                         

For Business Development, contact: Matthew Kuruc 732-274-2866,

Editor Details

Last Updated: 14-Sep-2021